Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn’s Colitides

Clinical Medicine Insights: Gastroenterology

Volumn 8, Issue , 2015, Pages 29-44

  Korolkova, Olga Y ^a   Myers, Jeremy N ^a   Pellom, Samuel T ^a   Wang, Li ^b   M’Koma, Amosy E ^a,b,c  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Biomarkers; Crohn s disease; Cytokines; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ALPHA2 INTERFERON; CYTOKINE; EOTAXIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FLT3 LIGAND; FRACTALKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMMUNOASSAY; MAGNETIC BEAD BASED MULTIPLEX IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; ULCERATIVE COLITIS;

EID: 84935033021     PISSN: None     EISSN: 11795522     Source Type: Journal    
DOI: 10.4137/Cgast.s20612     Document Type: Article

References (120)

1. Zhang Y, Li Y. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20:91-99.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
3. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006;12:4807-4812.
4. Iboshi Y, Nakamura K, Ihara E, et al. Multigene analysis unveils distinctive expression profiles of helper T-cell-related genes in the intestinal mucosa that discriminate between ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2014;20:967-977.
5. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1756-1767.
6. Sanchez-Mu�oz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008;14:4280-4288.
7. Biesiada G, Czepiel J, Ptak-Belowska A, et al. Expression and release of leptin and proinflammatory cytokines in patients with ulcerative colitis and infectious diarrhea. J Physiol Pharmacol. 2012;63:471-481.
8. Katsanos KH, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos EV. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res. 2001;11:364-367.
9. Brown KA, Back SJ, Ruchelli ED, et al. Lamina propria and circulating interleukin-6 in newly diagnosed pediatric inflammatory bowel disease patients. Am J Gastroenterol. 2002;97:2603-2608.
10. Kili� ZMY, Ayaz S, �zin Y, Nadir I, Cakal B, Ulker A. Plasma transforming growth factor-�1 level in inflammatory bowel disease. Turk J Gastroenterol. 2009;20:165-170.
11. Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-a in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem. 2001;47:1297-1301.
12. M'Koma AE, Wise PE, Muldoon RL, Schwartz DA, Washington MK, Herline AJ. Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones. Int J Colorectal Dis. 2007;22:1143-1163.
13. Tremaine WJ. Is indeterminate colitis determinable? Curr Gastroenterol Rep. 2012;14:162-165.
14. Mitchell PJ, Rabau MY, Haboubi NY. Indeterminate colitis. Tech Coloproctol. 2007;11:91-96.
15. Brown CJ, Maclean AR, Cohen Z, Macrae HM, O'Connor BI, McLeod RS. Crohn's disease and indeterminate colitis and the ileal pouch-anal anastomosis: outcomes and patterns of failure. Dis Colon Rectum. 2005;48:1542-1549.
16. M'Koma AE, Seeley EH, Washington MK, et al. Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides. Inflamm Bowel Dis. 2011;17:875-883.
17. Seeley EH, Washington MK, Caprioli RM, M'Koma AE. Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis. Proteomics Clin Appl. 2013;7:541-549.
18. Weitzman ED, Fukushima D, Nogeire C, Roffwarg H, Gallagher TF, Hellman L. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab. 1971;33:14-22.
19. Van Assche G, Dignass A, Panes J, et al; European Crohn's and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7-27.
20. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990.
21. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5A-36A.
22. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314-1321.
23. Cook MG, Dixon MF. An analysis of the reliability of detection and diagnostic value of various pathological features in Crohn's disease and ulcerative colitis. Gut. 1973;14:255-262.
24. Talstad I, Gjone E. The disease activity of ulcerative colitis and Crohn's disease. Scand J Gastroenterol. 1976;11:403-408.
25. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530.
26. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46.
27. Puri KS, Suresh KR, Gogtay NJ, Thatte UM. Declaration of Helsinki, 2008: implications for stakeholders in research. J Postgrad Med. 2009;55:131-134.
28. Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med. 2003;138:644-650.
29. Hyams JS, Fitzgerald JE, Wyzga N, Treem WR, Justinich CJ, Kreutzer DL. Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease. Dig Dis Sci. 1994;39:1893-1899.
30. Kader HA, Tchernev VT, Satyaraj E, et al. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-[beta]1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol. 2005;100:414-423.
31. Knutson CG, Mangerich A, Zeng Y, et al. Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease. Proc Natl Acad Sci U S A. 2013;110:E2332-E2341.
32. Propst A, Propst T, Herold M, Vogel W, Judmaier G. Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 1995;7:1031-1036.
33. Raddatz D, Bockem�hl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol. 2005;17:547-557.
34. Szkaradkiewicz A, Marciniak R, Chudzicka-Strugala I, et al. Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp. 2009;57:291-294.
35. Wine E, Mack DR, Hyams J, et al. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. J Crohns Colitis. 2013;7:916-922.
36. Toya Y, Chiba T, Mizutani T, et al. The effect of granulocyte and monocyte adsorptive apheresis on serum cytokine levels in patients with ulcerative colitis. Cytokine. 2013;62:146-150.
37. Rodr�guez-Perlv�rez ML, Garc�a-S�nchez V, Villar-Pastor CM, et al. Role of serum cytokine profile in ulcerative colitis assessment. Inflamm Bowel Dis. 2012;18:1864-1871.
38. Lacruz-Guzm�n D, Torres-Moreno D, Pedrero F, et al. Influence of polymorphisms and TNF and IL1� serum concentration on the infliximab response in Crohn's disease and ulcerative colitis. Eur J Clin Pharmacol. 2013;69:431-438.
39. Street ME, de'Angelis G, Camacho-H�bner C, et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflamm bowel disease. Horm Res. 2004;61:159-164.
40. Funderburg NT, Stubblefield Park SR, Sung HC, et al. Circulating CD4+ and CD8+ T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology. 2013;140:87-97.
41. Ohtani K, Ohtsuka Y, Ikuse T, et al. Increased mucosal expression of GATA-3 and STAT-4 in pediatric ulcerative colitis. Pediatr Int. 2010;52:584-589.
42. Nielsen OH, K�ppen T, R�diger N, Horn T, Eriksen J, Kirman I. Involvement of interleukin-4 and-10 in inflammatory bowel disease. Dig Dis Sci. 1996;41:1786-1793.
43. Holland N, Dong J, Garnett E, et al. Reduced intracellular T-helper 1 interferon-gamma in blood of newly diagnosed children with Crohn's disease and age-related changes in Th1/Th2 cytokine profiles. Pediatr Res. 2008;63:257-262.
44. Mitsuyama K, Tomiyasu N, Suzuki A, et al. A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease. Clin Exp Immunol. 2006;143:125-131.
45. Mitsuyama K, Tomiyasu N, Takaki K, et al. Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase. Mediators Inflamm. 2006;2006(6):26875.
46. Mitsuyama K, Toyonaga A, Sasaki E, et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut. 1995;36:45-49.
47. Mitsuyama K, Tsuruta O, Tomiyasu N, et al. Increased circulating concentrations of growth-related oncogene (GRO)-a in patients with inflammatory bowel disease. Dig Dis Sci. 2006;51:173-177.
48. Gombo�ov� L, Laz�rov� I, Zakuciov� M, et al. Genes of intestinal Escherichia coli and their relation to the inflammatory activity in patients with ulcerative colitis and Crohn's disease. Folia Microbiol. 2011;56:367-372.
49. Carey R, Jurickova I, Ballard E, et al. Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:446-457.
50. Umehara Y, Kudo M, Nakaoka R, Kawasaki T, Shiomi M. Serum proinflammatory cytokines and adhesion molecules in ulcerative colitis. Hepatogastroenterology. 2006;53:879-882.
51. Serada S, Fujimoto M, Terabe F, et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis. 2012;18:2169-2179.
52. Bross DA, Leichtner AM, Zurakowski D, Law T, Bousvaros A. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. J Pediatr Gastroenterol Nutr. 1996;23:164-171.
53. Gijsbers K, Van Assche G, Joossens S, et al. CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue. Eur J Immunol. 2004;34:1992-2000.
54. Alzoghaibi MA, Al-Mofleh IA, Al-Jebreen AM. Neutrophil chemokines GCP-2 and GRO-a in patients with inflammatory bowel disease. J Dig Dis. 2008;9:144-148.
55. Haas SL, Abbatista M, Brade J, Singer MV, B�cker U. Interleukin-18 serum levels in inflammatory bowel diseases: correlation with disease activity and inflammatory markers. Swiss Med Wkly. 2009;139:140-145.
56. Kucharzik T, Stoll R, L�gering N, Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol. 1995;100:452-456.
57. Oikonomou KA, Kapsoritakis AN, Kapsoritaki AI, et al. Downregulation of serum epidermal growth factor in patients with inflammatory bowel disease. Is there a link with mucosal damage? Growth Factors. 2010;28:461-466.
58. Manousou P, Kolios G, Valatas V, et al. Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in in vitro studies. Clin Exp Immunol. 2010;162:337-347.
59. Mir A, Minguez M, Tatay J, et al. Elevated serum eotaxin levels in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97:1452-1457.
60. Chen W, Paulus B, Shu D, Wilson V, Chadwick V. Increased serum levels of eotaxin in patients with inflammatory bowel disease. Scand J Gastroenterol. 2001;36:515-520.
61. Capobianchi MR, Fais S, Di Paolo MC, et al. Absence of circulating interferon in patients with inflammatory bowel disease. Suggestion against an autoimmune etiology. Clin Exp Immunol. 1992;90:85-87.
62. Krzystek-Korpacka M, Neubauer K, Matusiewicz M. Platelet-derived growth factor-BB reflects clinical, inflammatory and angiogenic disease activity and oxidative stress in inflammatory bowel disease. Clin Biochem. 2009;42:1602-1609.
63. Owczarek D, Cibor D, Glowacki MK, Ciesla A, Mach P. TNF-a and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn's disease and ulcerative colitis. Pol Arch Med Wewn. 2012;122:616-623.
64. Kapsoritakis A, Sfiridaki A, Maltezos E, et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis. 2003;18:418-422.
65. Wedrychowicz A, Kowalska-Duplaga K, Jedynak-Wasowicz U, et al. Serum concentrations of VEGF and TGF-1� during exclusive enteral nutrition in IBD. J Pediatr Gastroenterol Nutr. 2011;53:150-155.
66. Schmechel S, Konrad A, Diegelmann J, et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis. 2008;14:204-212.
67. Reinisch W, Gasch� C, Tillinger W, et al. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol. 1999;94:2156-2164.
68. Kirman I, Nielsen OH. Increased numbers of interleukin-15-expressing cells in active ulcerative colitis. Am J Gastroenterol. 1996;91:1789-1794.
69. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65-70.
70. Ohman L, Dahl�n R, Isaksson S, et al. Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease. Inflamm Bowel Dis. 2013;19:2433-2439.
71. Song L, Zhou R, Huang S, et al. High intestinal and systemic levels of interleukin-23/T-helper 17 pathway in Chinese patients with inflammatory bowel disease. Mediators Inflamm. 2013;2013:425915.
72. Ogawa K, Matsumoto T, Esaki M, Torisu T, Iida M. Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab. J Crohns Colitis. 2012;6:529-535.
73. Andreu-Ballester JC, Perez-Griera J, Garcia-Ballesteros C, et al. Deficit of interleukin-7 in serum of patients with Crohn's disease. Inflamm Bowel Dis. 2013;19:E30-E31.
74. Marlicz W, Zuba-Surma E, Kucia M, Blogowski W, Starzynska T, Ratajczak MZ.Various types of stem cells, including a population of very small embryonic-like stem cells, are mobilized into peripheral blood in patients with Crohn's disease. Inflamm Bowel Dis. 2012;18:1711-1722.
75. Chao K, Zhong BH, Zhang SH, Gong XR, Yao JY, Chen MH. [Imbalance of CD4(+) T cell subgroups in ulcerative colitis]. Zhonghua Yi Xue Za Zhi. 2011;91:1605-1608.
76. Nagase K, Fukunaga K, Kashiwamura S, et al. Immunoregulatory effects of adsorptive granulocyte and monocyte apheresis in patients with drug refractory Crohn's disease. Ther Apher Dial. 2011;15:367-373.
77. Zheng ZD, Wan XQ, Liu LY. Serum contents of IL-23 and IL-17 in the patients with ulcerative colitis and the clinical significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011;27:203-206.
78. Ajdukovic J, Tonkic A, Salamunic I, Hozo I, Simunic M, Bonacin D. Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative colitis. Hepatogastroenterology. 2010;57:1442-1444.
79. Liu Z, Chen X, Wang X, et al. Chemokine CXCL11 links microbial stimuli to intestinal inflammation. Clin Exp Immunol. 2011;164:396-406.
80. Wang AH, Lam WJ, Han DY, et al. The effect of IL-10 genetic variation and interleukin 10 serum levels on Crohn's disease susceptibility in a New Zealand population. Hum Immunol. 2011;72:431-435.
81. Frysz-Naglak D, Fryc B, Klimacka-Nawrot E, et al. Expression, localization and systemic concentration of vascular endothelial growth factor (VEGF) and its receptors in patients with ulcerative colitis. Int Immunopharmacol. 2011;11:220-225.
82. Kohut M, Hartleb M, Hartleb T. [Significance of serum concentrations of pro-and anti-inflammatory cytokines in identification of patients with Crohn's disease]. Pol Merkur Lekarski. 2010;29:169-172.
83. Figueredo CM, Brito F, Barros FC, et al. Expression of cytokines in the gingival crevicular fluid and serum from patients with inflammatory bowel disease and untreated chronic periodontitis. J Periodontal Res. 2011;46:141-146.
84. Pousa ID, Algaba A, Linares PM, et al. Corticosteroids modulate angiogenic soluble factors in ulcerative colitis patients. Dig Dis Sci. 2011;56:871-879.
85. Ciecko-Michalska I, Fedak D, Mach T. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease]. Przegl Lek. 2010;67:1262-1265.
86. Ksiadzyna D, Semianow-Wejchert J, Nawrot U, Wlodarczyk K, Paradowski L. Serum concentration of interleukin 10, anti-mannan Candida antibodies and the fungal colonization of the gastrointestinal tract in patients with ulcerative colitis. Adv Med Sci. 2009;54:170-176.
87. Guti�rrez A, Franc�s R, Amor�s A, et al. Cytokine association with bacterial DNA in serum of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:508-514.
88. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008;6:1218-1224.
89. Maor I, Rainis T, Lanir A, Lavy A. Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn's disease: distinction between active and non-active disease. Dig Dis Sci. 2008;53:2208-2214.
90. Noguchi A, Watanabe K, Narumi S, et al. The production of interferon-gamma-inducible protein 10 by granulocytes and monocytes is associated with ulcerative colitis disease activity. J Gastroenterol. 2007;42:947-956.
91. Due�as Pousa I, Mat� Jim�nez J, Salcedo Mora X, Abreu MT, Moreno Otero R, Gisbert JP. Analysis of soluble angiogenic factors in Crohn's disease: a preliminary study. Gastroenterol Hepatol. 2007;30:518-524.
92. Nancey S, Hamzaoui N, Moussata D, Graber I, Bienvenu J, Flourie B. Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Dig Dis Sci. 2008;53:242-247.
93. Pastor Rojo O, L�pez San Rom�n A, Alb�niz Arbizu E, de la Hera Mart�nez A, Sevillano E, Albillos Mart�nez A. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:269-277.
94. Wiercinska-Drapalo A, Jaroszewicz J, Parfieniuk A, Lapinski TW, Rogalska M, Prokopowicz D. Pigment epithelium-derived factor in ulcerative colitis: possible relationship with disease activity. Regul Pept. 2007;140:1-4.
95. Pamuk GE, Vural O, Turgut B, Demir M, Umit H, Tezel A. Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis: a comparative study. Am J Hematol. 2006;81:753-759.
96. Di Sabatino A, Ciccocioppo R, Armellini E, et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflamm Bowel Dis. 2004;10:573-577.
97. Magro F, Araujo F, Pereira P, Meireles E, Diniz-Ribeiro M, Velosom FT. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci. 2004;49:1265-1274.
98. Boubaker J, Feki M, Hsairi M, et al. [Osteoporosis and inflammatory bowel disease: prevalence and risk factors in Tunisian patients]. Gastroenterol Clin Biol. 2003;27:901-907.
99. Nielsen HJ, Mortensen T, Holten-Andersen M, Br�nner N, S�rensen S, Rask-Madsen J. Increased levels of specific leukocyte-and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol. 2001;36:265-269.
100. Griga T, Werner S, K�ller M, Tromm A, May B. Vascular endothelial growth factor (VEGF) in Crohn's disease: increased production by peripheral blood mononuclear cells and decreased VEGF165 labeling of peripheral CD14+ monocytes. Dig Dis Sci. 1999;44:1196-1201.
101. Bousvaros A, Leichtner A, Zurakowski D, et al. Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease. Dig Dis Sci. 1999;44:424-430.
102. Brandt E, M�ller-Alouf H, Desreumaux P, Woerly G, Colombel JF, Capron M. Circulating growth-regulator oncogene alpha contributes to neutrophil priming and interleukin-8-directed mucosal recruitment into chronic lesions of patients with Crohn's disease. Eur Cytokine Netw. 1998;9:647-653.
103. Straub RH, Vogl D, Gross V, Lang B, Sch�lmerich J, Andus T. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am J Gastroenterol. 1998;93:2197-2202.
104. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93:1483-1490.
105. Griga T, Tromm A, Spranger J, May B. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand J Gastroenterol. 1998;33:504-508.
106. Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr. 1997;24:289-295.
107. Holtkamp W, Stollberg T, Reis HE. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. J Clin Gastroenterol. 1995;20:123-126.
108. Jones SC, Evans SW, Lobo AJ, Ceska M, Axon AT, Whicher JT. Serum interleukin-8 in inflammatory bowel disease. J Gastroenterol Hepatol. 1993;8:508-512.
109. Hyams JS, Fitzgerald JE, Treem WR, Wyzga N, Kreutzer DL. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology. 1993;104:1285-1292.
110. Gross V, Andus T, Caesar I, Roth M, Sch�lmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology. 1992;102:514-519.
111. Mahida YR, Kurlac L, Gallagher A, Hawkey CJ. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut. 1991;32:1531-1534.
112. Hyams JS, Treem WR, Eddy E, Wyzga N, Moore RE. Tumor necrosis factor-alpha is not elevated in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1991;12:233-236.
113. Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in the serum of healthy subjects. Mediators Inflamm. 2013;2013:6.
114. Rudack C, Maune S, Eble J, Schroeder JM. The primary role in biologic activity of the neutrophil chemokines IL-8 and GRO-a in cultured nasal epithelial cells. J Interferon Cytokine Res. 2003;23:113-123.
115. Keustermans GC, Hoeks SB, Meerding JM, Prakken BJ, de Jager W. Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples. Methods. 2013;61:10-17.
116. Zander J, Bruegel M, Kleinhempel A, et al. Effect of biobanking conditions on short-term stability of biomarkers in human serum and plasma. Clin Chem Lab Med. 2014;52:629-639.
117. Korczowska I, Lacki JK, Hrycaj P. Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients. Yonsei Med J. 2013;54:183-188.
118. Marques-Vidal P, Bochud M, Bastardot F, et al. Levels and determinants of inflammatory biomarkers in a Swiss population-based sample (CoLaus study). PLoS One. 2011;6:e21002.
119. Cartier A, C�t� M, Lemieux I, et al. Age-related differences in inflammatory markers in men: contribution of visceral adiposity. Metabolism. 2009;58:1452-1458.
120. Stafford SJ, Wilson RR. An isolated case of leprosy presenting in a migrant worker in Northern Ireland. Emerg Med J. 2006;23:699-700.